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Multiple sclerosis is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue
injury in the CNS. The structural and immunopathological patterns of demyelination suggest that different
immune mechanisms may be involved in tissue damage. In a subtype of lesions, which are mainly found in
patients with acute fulminant multiple sclerosis with Balo’s type concentric sclerosis and in a subset of early
relapsing remitting multiple sclerosis, the initial myelin changes closely resemble those seen in white matter
stroke (WMS), suggesting a hypoxia-like tissue injury. Since mitochondrial injury may be involved in the patho-
genesis of such lesions, we analysed a number of mitochondrial respiratory chain proteins in active lesions from
acute multiple sclerosis and fromWMS using immunohistochemistry. Functionally important defects of mito-
chondrial respiratory chain complex IV [cytochrome c oxidase (COX)] including its catalytic component
(COX-I) are present in Pattern III but not in Pattern IImultiple sclerosis lesions.The lack of immunohistochemi-
cally detected COX-I is apparent in oligodendrocytes, hypertrophied astrocytes and axons, but not inmicroglia.
The profile of immunohistochemically detected mitochondrial respiratory chain complex subunits differs
between multiple sclerosis and WMS.The findings suggest that hypoxia-like tissue injury in Pattern III multiple
sclerosis lesions may be due to mitochondrial impairment.
Keywords: multiple sclerosis; Pattern III lesion; mitochondria; cytochrome c oxidase
Abbreviations: CNPase=cyclic nucleotide phosphodiesterase; COX=cytochrome c oxidase; LFB=Luxol fast blue;
MAG=myelin associated glycoprotein; MBP=myelin basic protein; mtDNA=mitochondrial DNA; NO=nitric oxide;
NWM=normal white matter; PLP=proteolipid protein; WMS=white matter stroke
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Introduction
Multiple sclerosis is an inflammatory demyelinating disease
of the central nervous system with axonal degeneration and
astrogliosis (Frohman et al., 2006). The loss of myelin
in multiple sclerosis may be the result of direct damage
to myelin through immune mediated processes and/or
dysfunction of oligodendrocytes (Lassmann et al., 2001;
Barnett and Prineas, 2004). A particular subtype of active
multiple sclerosis lesions (Pattern III, Lucchinetti et al
2000), which are mainly found in patients with acute fulmi-
nant multiple sclerosis with Balo’s type concentric sclerosis
and in a subset of early relapsing remitting multiple
sclerosis, has been defined by the selective early loss of
myelin associated glycoprotein (MAG) and cyclic nucleotide
phosphodiesterase (CNPase) together with apoptotic cell
death of oligodendrocytes (Itoyama et al., 1980; Lucchinetti
et al., 2000; Barnett and Prineas, 2004; Stadelmann et al.,
2005). Indirect evidence suggests that hypoxia-like tissue
injury may play a role in their pathogenesis. A comparable
loss of MAG and CNPase together with oligodendrocyte
apoptosis is also seen in initial lesions in white matter
stroke (WMS) and hypoxia inducible factor-1, a tran-
scription factor induced in hypoxic condition, is expressed
in such multiple sclerosis and WMS lesions (Aboul-Enein
et al., 2003; Stadelmann et al., 2005). Profound microglia
and macrophage activation with expression of inducible
nitric oxide synthase (i-NOS) and myeloperoxidase is
another characteristic feature of such multiple sclerosis
lesions (Stadelmann et al., 2005; Marik et al., 2007).
Reactive oxygen species and nitric oxide (NO), pro-
duced by these enzymes, may impair mitochondrial
function (Bolanos et al., 1997) and thus may link
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microglial activation in such lesions with a hypoxia-like
tissue injury.
Mitochondria contain the respiratory chain where energy
in the form of ATP is most efficiently produced (DiMauro
and Schon, 2003). Mitochondria also play an important
role in apoptosis and calcium homeostasis (Rizzuto and
Pozzan, 2006; Kalman et al., 2007). The mitochondrial
respiratory chain is located in the inner mitochondrial
membrane and consists of four complexes (complexes I–IV,
Fig. 1) whilst complex V is directly involved in ATP syn-
thesis (DiMauro and Schon, 2003). The complexes of the
mitochondrial respiratory chain are made up of multiple
subunits and all but complex II (which is entirely encoded
by nuclear DNA) contain proteins encoded by nuclear and
mitochondrial DNA (mtDNA) (Taylor and Turnbull, 2005).
The final respiratory chain complex [complex IV or cyto-
chrome c oxidase (COX)] is the site at which over 90% of
oxygen is consumed (DiMauro and Schon, 2003). This
complex is also involved in proton pumping, essential for
ATP synthesis (DiMauro and Schon, 2003). NO competi-
tively inhibits the binding of oxygen to complex IV (Brown
and Cooper, 1994; Cleeter et al., 1994). NO, when over-
expressed, may irreversibly impair the activity of mitochon-
drial respiratory chain complexes I and IV via perxoynitrite
(Clementi et al., 1998; Smith and Lassmann, 2002; Zhang
et al., 2005). In pathological states, histotoxic hypoxia may
be induced by the inability to use available oxygen,
when complex IV is blocked by persistently increased
NO levels (Moncada and Erusalimsky, 2002). Three of the
four oxygen binding sites [heme (a and a3) and copper
(CuB) cofactors] are located in subunit-I of complex IV
(COX-I), which is the vital component of the catalytic
core (Taanman and Williams, 2001). COX-I, encoded
by mtDNA, is highly conserved in eukaryotic cells
(Taanman and Williams, 2001; Taylor and Turnbull, 2005).
The loss of COX-I renders complex IV inactive as reported in
patients with mitochondrial disease due to pathogenic
mutations of COX-I gene and prevents utilization of oxygen
(Clementi et al., 1998; Bruno et al., 1999; Kollberg et al., 2005).
Based on the evidence that NO impairs mitochondrial
respiratory chain complexes, HIF-1 regulates the composi-
tion of subunits of complex IV and NO and HIF-1 are
present in Pattern III multiple sclerosis lesions, we
hypothesized that defects in mitochondrial respiratory
chain complexes may be involved in hypoxia-like tissue
damage in Pattern III lesions of multiple sclerosis patients.
Materials and Methods
Autopsy tissue
Paraffin embedded brain tissue from acute multiple sclerosis cases
is part of the well-characterized archival material used to identify
the four patterns of acute multiple sclerosis lesions (MS1–MS9,
Table 1) (Lucchinetti et al., 2000). Tissue from WMS cases
(WMS1–WMS6, Table 1) containing lesions with active demye-
lination was provided by the University of Vienna (Aboul-Enein
et al., 2003). Control tissue (CON1–CON8, Table 1) was provided
by the UK multiple sclerosis tissue resource, London. Although
the exact post-mortem delay for the acute multiple sclerosis cases
Fig. 1 The mitochondrial respiratory chain. The mitochondrial respiratory chain consists of four complexes (complexes I^IV) and
complex V, which is directly involved in ATP synthesis. The complexes are made up of multiple subunits encoded by nuclear DNA and
mtDNA, except complex II which is entirely encoded by nuclear DNA.We investigated two subunits of complex I (20 and 30kDa), one of
complex II (70kDa) and two of complex IV (subunits I and IV of complex IV or COX-I and COX-IV, respectively) in brain tissue. Porin, a
voltage gated anion channel located in the outer mitochondrial membrane, was used as a mitochondrial marker. The activity of succinate
dehydrogenase (complex II) and COX (complex IV) can be determined at the single cell level using an enzyme histochemical assay (COX/
succinate dehydrogenase histochemistry). NO inhibits complex IV activity by competing with oxygen for the oxygen binding sites, of which
three out of the four are located in COX-I. Both complexes I and IV are susceptible to peroxynitrite (ONOO) mediated damage.
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are unknown, the tissue is well preserved with respect to detection
of mRNA by in situ hybridization as well as protein epitopes by
immunohistochemistry. For fixed control tissue, the range for
post-mortem time is 4–63 h (median = 18). The cause of death for
all multiple sclerosis cases and controls (Table 1) was either
cardiorespiratory failure/arrest or pneumonia. The control cases
had underlying carcinomatosis originating from bowel or prostate.
For validation of immunoreactivity of monoclonal antibodies
against a number of mitochondrial respiratory chain complex
subunits in fixed brain tissue, both paraffin embedded and frozen
hippocampal sections were used from a case with multiple
mtDNA deletions (Taylor and Turnbull, 2005). The Newcastle
and North Tyneside Local Research Ethics Committee approved
the study (205/Q0906/182).
Immunohistochemistry
Following rehydration of fixed and paraffin embedded sections
(5mm thickness) antigen retrieval was performed using EDTA
buffer pH 8.0. The endogenous peroxidase activity was blocked
using 3% hydrogen peroxide for 30min and non-specific antibody
binding was prevented by blocking sections in 1% normal goat
serum (Sigma) for 30min prior to incubation with the primary
antibody (Table 2). Both mtDNA and nuclear DNA encoded
Table 1 Details of autopsy cases
Case No. Age (years)/Sex Diagnosis No. of blocks No. of lesions Duration of disease
MS1 45/F Acute multiple sclerosis (Pattern III) 2a 3 1week
MS2 45/F Acute multiple sclerosis (Pattern III) 1 1 2 months
MS3 35/M Acute multiple sclerosis (Pattern III) 2a 3 1.5 months
MS4 44/F Acute multiple sclerosis (Pattern III) 2a 3 2 weeks
MS5 40/F Acute multiple sclerosis (Pattern III) 2 2 120 months
MS6 46/F Acute multiple sclerosis (Pattern II) 2 2 3 months
MS7 51/F Acute multiple sclerosis (Pattern II) 2 3 5 months
MS8 52/M Acute multiple sclerosis (Pattern II) 2 3 1.5 months
MS9 20/F Acute multiple sclerosis (Pattern II) 1 1 4 years
WMS1 51/F WMS 1 1 2 weeks
WMS2 66/M WMS 1 2 1.5 months
WMS3 68/M WMS 1 2 1week
WMS4 85/F WMS 1 2 1.5 months
WMS5 90/F WMS 1 2 0.6 weeks
WMS6 85/F WMS 1 1 1.1weeks
CON1 85/M NND 2 NA NA
CON2 89/M NND 2 NA NA
CON3 57/M NND 2 NA NA
CON4 95/F NND 2 NA NA
CON5 67/F NND 2 NA NA
CON6 64/F NND 2 NA NA
CON7 88/M NND 2 NA NA
CON8 76/F NND 2 NA NA
CON=control; NA=not applicable; NND=non-neurological disease (carcinomatosis originating from bowel or prostate).
aThe large sections measured 4.53 cms.
Table 2 Details of antibodies used for immunohistochemistry
Antigen Encoding DNA Antibody type Source
MBP (SMI 94) ^ mouse IgG1 Sternberger
PLP ^ mouse IgG Serotec
MAG (D7E10) ^ mouse IgG (Dobersen et al., 1985)
CNPase ^ mouse IgG1 Sternberger
HLA-DP, DQ and DR ^ mouse IgG1 Dako
CD163 ^ mouse IgG1 Novocastra
Glial fibrillary acidic protein ^ rabbit polyclonal Dako
Phosphorylated NF (SMI 31) ^ mouse IgG1 Sternberger
Non-phosphorylated NF (SMI32) ^ mouse IgG1 Sternberger
Porin Nuclear mouse IgG2b Invitrogen
Complex I-20 kDa (MTND6) Mitochondrial mouse IgG1 Invitrogen
Complex I-30 kDa (NDUFS3) Nuclear mouse IgG1 Invitrogen
Complex II 70kDa (SDHA) Nuclear mouse IgG2a Invitrogen
Complex IV subunit-I or COX-I (MTCO1) Mitochondrial mouse IgG2a Invitrogen
Complex IV subunit-IV or COX-IV (COX4) Nuclear mouse IgG2a Invitrogen
Gene number.
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subunits were included for the immunohistochemical detection
(Rahman et al., 2000; Taylor and Turnbull, 2005). The secondary
antibody (goat anti-mouse or goat anti-rabbit, Vector), avidin-
biotin amplification system with peroxidase (Vector) and diamino
benzidine tetrahydrochloride (DAB, Sigma) were used according
to manufactures protocols. The sections were counter stained with
hematoxylin prior to dehydration and mounting. Serial sections
from each block were used for staining with antibodies against
mitochondrial respiratory chain subunits and porin, a voltage-
dependant anion channel expressed on the outer mitochondrial
membrane (Table 2). For co-staining using chromogens (DAB and
Vector SG) one anti-mitochondrial respiratory chain subunit
antibody was developed with DAB (brown) and then the sections
were re-blocked and incubated with anti-glial fibrillarry acidic
protein antibody which was detected using HRP conjugated anti-
rabbit secondary antibody (DAKO) and Vector SG (grey). The
appropriate control experiments were performed to exclude cross
reactivity of secondary antibodies.
Immunofluorescent histochemistry
Dual immunofluorescence was utilized for cellular localization of
mitochondrial respiratory chain subunits. The paraffin embedded
tissue sections were prepared as for immunohistochemistry with-
out hydrogen peroxide. The pairs of primary antibodies were
co-incubated for 90min at room temperature followed by two
subtype specific secondary antibodies (Jackson immunoresearch),
one rhodamine conjugated and other biotinylated. The biotiny-
lated secondary antibody was amplified using streptavidin
fluoroisothiocyanate (Alexis). The sections were mounted using
Vectashield with DAPI (Vector). Lack of cross reactivity and non-
specific binding of secondary antibodies was determined using
appropriate controls.
Histochemistry
For detection of complex IV activity within individual cells in the
case with primary mitochondrial disease, frozen hippocampal
sections (8 mm) were air dried for 60min at room temperature
prior to incubation in COX medium (100 mM cytochrome c,
4mM diaminobenzidine tetrahydro-chloride and 20 mg/ml catalase
in 0.2M phosphate buffer, pH 7.0) at 37C for 50min (Clark
et al., 1997). To detect mitochondrial elements that lack complex
IV activity, the activity of complex II (unaffected by the mtDNA
deletions) was determined by incubating in succinate dehydro-
genase medium (130mM sodium succinate, 200 mM phenazine
methosulphate, 1mM sodium azide, 1.5mM nitroblue tetrazolium
in 0.2M phosphate buffer, pH 7.0) at 37C for 40min once the
incubation in COX medium for 50min and the subsequent
washing steps were completed. Following histochemistry, the
sections were dehydrated in 70, 90 and 100% ethanol followed
by Histoclear (National Diagnostics, Atlanta, Georgia, USA) and
mounted in Glycerol (Citifluor).
Lesion classification
The Pattern III lesions in the early active (EA) stage (n= 12),
including Balo’s type, were identified based on the preferential
loss of MAG or CNPase and the absence of immunoglobulins
and complement deposition, as previously described (Lucchinetti
et al., 2000). In contrast, Pattern II lesions, similarly staged by the
presence of early myelin degradation products in macrophages
(n=9), show a comparable loss of MAG and other myelin com-
ponents [myelin basic protein (MBP), proteolipid protein (PLP)
and myelin oligodendrocyte glycoprotein]. The EA regions of
WMS lesions (n=10) showed preferential loss of MAG and
CNPase as in Pattern III lesions. The late active (LA) regions of all
lesion types are demyelinated and contain phagocytic macrophages
with only the major myelin degradation products (MBP, PLP and
myelin oligodendrocyte glycoprotein). All lesion types show
inflammatory activity as shown by HLA staining. No lesions
were present in control tissue. The two stages of demyelination
(EA and LA) were present in all Pattern III, 8 of the 9 Pattern II
and 9 of the 10 WMS lesions. One Pattern II lesion and one
WMS lesion contained only a LA and EA stage, respectively. The
regions of ‘normal’ white matter (NWM), without macroscopic or
histological evidence of demyelination, were identified as internal
controls for Pattern III (n= 12), Pattern II (n= 9) and WMS
(n=10) lesions.
Confocal laser fluorescence microscopy
The sections double labelled for mitochondrial proteins and neuro-
filaments (SMI31 and SMI32) or CNPase using immunofluores-
cence were analysed on a Leica laser scanning microscope
(Heidelberg, Germany). Individual optical sections with 1 mm
thickness were taken through the tissue sections. The minimum
number of optical sections was combined to track axons in
Pattern III lesions. fluoroisothiocyanate and TRIC channels were
imaged sequentially and the optimal number of images stacked to
ensure that the yellow elements are a result of co-localisation
rather than superimposition of non-axonal porin (fluoroisothio-
cyanate) elements. The offset and gain were kept constant during
imaging of all sections. A single x–z optical section was taken
through axons.
Quantification of mitochondrial respiratory
chain complex subunit immunoreactivity in
fixed brain tissue
Due to the ubiquitous nature of mitochondrial immunoreactivity
in the brain, the immunoreactive elements were captured using a
100 oil lens (Axioplan, Zeiss) and the well demarcated punctate
elements were manually counted in two 100 fields (6044 mm2/field)
for each lesion stage and NWM of every acute multiple sclerosis and
WMS case. We also counted the immunoreactive elements within
individual hippocampal cells from the case with mtDNA deletions.
The assessors were blinded to tissue type and lesion stage. In order
to correct for loss of tissue and/or mitochondria, the immunor-
eactivity of mitochondrial respiratory chain complex subunits is
calculated as a percentage of porin immunoreactivity within each
region in serial sections. The difficulty in identifying individual
immunoreactive elements within cell bodies of glia limited the
manual quantitation of immunoreactivity within hypertrophied
astrocytes and activated microglia, which were excluded from this
analysis. As the second method of analysis, the optical density of grey
scale 100 images with identical exposure times were measured
using densitometry (Zeiss Axiovision), which included immuno-
reactive elements within glia.
Statistical analysis
Parametric tests (ANOVA) and SPSS version 14 were used for
statistical analysis of immunoreactivity in multiple sclerosis, WMS
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and control white matter cases as well as the mitochondrial case.
The immunoreactivity within lesion stages were compared with
the corresponding NWM in multiple sclerosis and WMS cases
using the posttest (Newman-Keuls), when ANOVA test indicated
a P-value of50.05.
Results
Since hypoxia-like tissue injury, described in a subset of
multiple sclerosis lesions (Pattern III, Lucchinetti et al.,
2000), may be caused by mitochondrial dysfunction we
analysed the expression patterns of mitochondrial proteins
in these lesions in comparison to that in other multiple
sclerosis lesions (Pattern II) and control brain white matter
by quantitative immunohistochemistry (Lucchinetti et al.,
2000). We then correlated our findings in multiple sclerosis
with those seen in lesions of acute WMS and mitochondrial
encephalopathy.
Pattern III multiple sclerosis lesions show
alterations in the expression of
mitochondrial proteins, mainly affecting
COX-I and COX-IV
Pattern III lesions in multiple sclerosis are inflammatory
demyelinating lesions with profound microglial activation
(Fig. 2a and b). In the EA stage, they are characterized by
reduced myelin density in Luxol fast blue (LFB) stained
sections (Fig. 2a) and a prominent loss of MAG (Fig. 2c)
and CNPase, while other myelin proteins remain preserved
(Fig. 2d). In more advanced lesions, called LA lesions,
myelin is completely lost (Fig. 2a, c and d). Some of
the lesions may show concentric rims of demyelinated
and myelinated tissue (Fig. 2a, c and d). Staining for
mitochondrial proteins revealed a profound loss of COX-I
(Fig. 2e and g) and COX-IV of complex IV (Fig. 2i) in EA
and LA lesion areas, while a general reduction of mito-
chondrial density, visualized also by reduction of porin
immunoreactivity, was mainly seen in LA lesions where
vacuolation of tissue is particularly apparent.
This general impression was confirmed by two indepen-
dent quantitative methods. The analysis of optical density
of affected tissue revealed significant reduction of mito-
chondrial immunoreactive signal for COX-I in both EA
(P50.01) and LA lesional stages (P50.001) in comparison
to that in NWM. Counting individual immunoreactive
mitochondrial profiles revealed significant reduction of
COX-I reactive elements in the EA stage (Table 3). In the
LA stage, the number of immunoreactive mitochondria
was reduced with all markers used, the most profound
reduction was seen for COX-I and COX-IV (Table 3).
When the number of COX-I reactive elements was correc-
ted for porin in serial section, the percentage of porin
stained mitochondria, which expressed COX-I was reduced
to 69 in EA and 43 in LA stages. A profound reduction of
immunoreactive mitochondria was also seen for COX-IV in
the LA stage (Table 3).
The defect in the catalytic subunit of complex
IV (COX-I) in Pattern III multiple sclerosis
lesions involves oligodendrocytes, axons
and astrocytes, but not macrophages and
microglia
In the next step we analysed mitochondrial immunoreac-
tivity in different cell types within active multiple sclerosis
lesions by double labelling immunohistochemistry and
confocal laser microscopy. The absence or massive decrease
of COX-I reactivity was seen in oligodendrocytes (Fig. 3a),
axons (Fig. 3c) as well as in a subpopulation (50%) of
glial fibrillary acidic protein positive astrocytes (Fig. 3e),
despite the abundance of porin reactive mitochondria in
the same cellular sites (Fig. 3b, d and f).
The mitochondria located within activated microglia in
EA and LA stages of Pattern III multiple sclerosis lesions
retain COX-I immunoreactivity despite the diffuse reduc-
tion in COX-I immunoreactivity involving other cell types
in the same regions (Fig. 3g–i).
No cellular mitochondrial defects are detect-
able in Pattern II multiple sclerosis lesions
As in Pattern III, Pattern II multiple sclerosis lesions
develop on the background of inflammation with activation
of complement (Marik et al., 2007). In EA stages
perivenous sheaths of demyelination are seen, which are
separated by areas of partly preserved myelin with abundant
macrophages, containing early myelin degradation products
(Fig. 4a and b). In contrast to Pattern III multiple sclerosis
lesions, there is no preferential loss of MAG or CNPase
in comparison to other myelin proteins (Fig. 4c and d).
At higher magnification, the tissue in EA and LA stages
appears vacuolated, due to profound oedema, which
extends into the adjacent NWM. A general reduction in
the density of mitochondrial profiles, seen in quantitative
analysis (Table 3), reflects the absence of mitochondria in
oedematous vacuoles (Fig. 4e and f). Within the cellular
profiles, however, mitochondrial density is not reduced in
comparison to that seen in the NWM of controls. We did
not find significant changes in the expression of different
mitochondrial proteins between NWM of controls and
Pattern II multiple sclerosis lesions, when the expression is
corrected for porin containing elements (Table 3).
Widespread defects of mitochondrial
respiratory chain complexes inWMS lesions
The transcription of mtDNA and nuclear DNA encoded
subunits of the mitochondrial respiratory chain complexes
are modulated by hypoxia (Vijayasarathy et al., 2003;
Piruat and Lopez-Barneo, 2005; Fukuda et al., 2007).
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Fig. 2 Pattern III multiple sclerosis lesions. (a^d) The brain sections containing Pattern III and Balo’s type (with concentric rings of
preserved myelin) active multiple sclerosis lesions are stained for LFB (a), HLA (b), MAG (c)and PLP (d). There is reduced density of LFB
staining (a, asterisks) in the EA stage, whereas LFB staining is absent (a, arrows) in the LA stage of Pattern III lesions compared with
NWM.The neuropathological hallmark of Pattern III lesions is the preferential loss of MAG, as indicated here by the loss of MAG
immunoreactivity (c, asterisks) and intact PLP immunoreactivity (d, asterisks) in the EA stage. In contrast, MAG and PLP immunoreactivity
is lost in the LA stage of Pattern III lesions (c and d, arrows). e and f: In deeper sections from the same block, there is a decrease in complex
IV subunit-I (COX-I) immunoreactivity, which is diffuse in the EA stage (e, asterisks) and most prominent in the LA stage (e, arrows)
compared with NWM.The porin immunoreactivity in the EA stage (f, asterisks) of Pattern III lesions is similar to the NWM. However,
there is a decrease in porin immunoreactivity in the LA stage (f, arrows). Interestingly, COX-I immunoreactivity is preserved in the
concentric rings of the Balo’s type multiple sclerosis lesion (e). g^i: Higher magnification images show the punctate COX-I (g), porin (h)
and COX-IV (i) immunoreactive elements, typical of mitochondrial staining, in the NWM (left column), EA stage (middle column) and LA
stage (right column). There is a global reduction in the number of COX-I immunoreactive elements in the EA (gg) and LA (ggg) stages of
Pattern III lesions compared with NWM (g). There are ramified cells consistent with microglia containing dense COX-I immunoreactivity
in Pattern III lesions (gg^ggg). The number of porin immunoreactive elements appears reduced in LA (hhh), where there is tissue
vacuolation, but not EA (hh) stage compared with NWM (h).The cells with enlarged cytoplasm (consistent with hypertrophied astrocytes)
contain a peripheral rim of dense porin (hhh) but not COX-I (ggg) immunoreactivity, and clearly illustrate the disproportionate loss of
COX-I compared with porin immunoreactivity in Pattern III lesions. The number of COX-IV immunoreactive elements is also decreased
in Pattern III lesions (ii and iii) compared with NWM (i). Scale bars = 8mm (a^f) and 10mm (g^i).
Mitochondrial defects in acute multiple sclerosis lesions Brain (2008), 131, 1722^1735 1727
Therefore, we immunohistochemically analysed mitochon-
drial respiratory chain subunits in WMS lesions (Table 4).
Similar to Pattern III multiple sclerosis lesions, the EA stage
of WMS lesions is characterized by the loss of MAG
and CNPase, while other myelin proteins are preserved
(Aboul-Enein et al., 2003). In the LA stage tissue is severely
damaged, reflected by global loss of myelin, profound
axonal degeneration and astrocytic damage (Fig. 5a–bbb).
In contrast to multiple sclerosis Pattern III lesions, all the
mtDNA and nuclear DNA encoded mitochondrial proteins,
with the exception of complex IV, were reduced in the EA
stage (Fig. 5c–hhh, Table 4). When corrected for porin
expression a significant decrease of mitochondrial immuno-
reactivity was seen for COX-I, complex I 20 kDa or ND6,
complex I 30 kDa and complex II 70 kDa proteins, but not
for COX-IV. In LA lesions, where tissue loss is extensive,
we found a general loss of mitochondria (including porin
reactive elements) except within phagocytic macrophages
(Fig. 5ccc–hhh). These data show, that Pattern III multiple
sclerosis as well as WMS lesions are associated with
mitochondrial injury, but that the profiles of mitochondrial
injury are different.
Reduced mitochondrial respiratory
chain complex subunit immunoreactivity
is associated with decreased functional
complex IVactivity in mitochondrial
encephalopathy
So far we have shown that the expression of mitochondrial
proteins, in particular COX-I and COX-IV, is reduced in
oligodendrocytes, axons and astrocytes in Pattern III mul-
tiple sclerosis lesions and that this reduction is associated
with a hypoxia-like tissue injury. The question thus arises,
whether such a decrease in mitochondrial proteins may
result in a functional defect of the respiratory chain.
This can be analysed in frozen tissue sections at the
single cell level using enzyme histochemistry for COX
Table 3 Quantitation of immunoreactive elements of mitochondrial respiratory chain subunits and porin in Patterns II and III
multiple sclerosis lesions and control white matter
Antigen mean  SD
(No. of lesions)
Porin COX-I
(mtDNA)
COX-IV
(nuclear)
Complex I
20kDa or
ND6 (mtDNA)
Complex I
30kDa
(nuclear)
Complex II
70kDa
(nuclear)
CON WM 228.8 23.3 207.216.9 152.412.8 141.016.5 139.317.3 119.513.4
 SD ^ 94.16.8 66.0 8.5 67.412.7 60.0 9.8 54.7 9.5
(12) 136.14.1 144.5 5.6 151.7 3.9 159.6 5.5 147.6 4.3 160.8 3.7
Pattern III MS 202.133.9 185.417.5 144.2 27.8 131.416.9 115.4 26.9 92.912.8
NWM ^ 93.111.6 70.916.5 66.411.9 61.78.5 43.9 8.8
(12) 135.8 4.1 141.53.6 160.5 5.1 157.13.8 144.33.7 161.74.7
Pattern III MS 193.126.6 131.017.6 112.4 24.7 141.117.8 104.718.5 101.416.4
EA ^ 69.0 7.5y 57.7 9.3 71.18.2 53.312.7 5513.7
(9^12) 132.9 4.9 170.4 5.1y 166.4 5.2 160.33.2 142.63.3 157.8 4.8
Pattern III MS 81.7 22.2 38.813.1 37.7 9.3y 53.7 22.6 43.322.7 49.0 8.9
LA ^ 43.3 6.1 47.4 7.3y 66.712.1 54.310.0 58 6.4
(10^12) 158.8 4.1 180.95.8 177.9 4.7y 162.24.1 143.43.9 155.6 4.7
Pattern II MS 198.627.9 179.414.7 130.7 25.2 128.717.5 111.810.0 88.3 9.9
NWM ^ 89.4 9.5 68.815.2 64.3 9.6 58.110.2 38 5.8
(8^9) 135.453.3 141.13.8 154.74.3 157.14.2 148.2 5.8 159.53.9
Pattern II MS 143.419.6y 111.3 8.2 99.515.3 92.814.7 75.9 9.7 104.69.4
EA ^ 79.9 8.1 71.911.7 66.112.6 53.3 9.9 40 7.4
(7^8) 128.9 4.1 144.75.7 152.33.3 156.9 4.7 146.43.9 157.24.2
Pattern II MS 138.314.8y 118.611.5 87.912.4 86.912.6 77.110.2 76.8 9.9
LA ^ 82.2 9.5 68.8 9.4 65.6 8.5 54.910.4 48 6.2
(8^9) 125.14.1 138.8 3.8 150.74.2 154.3 4.3 142.6 5.1 155.53.8
The values indicated in the first line are the mean and standard deviation of the absolute number of punctate elements per 100x field
(6044mm2), second line are the mean and standard deviation of the percentages of porin elements containing respiratory chain complex
subunit immunoreactivity (in serial sections) and third line are the mean and standard deviation of the densitometric values of whole grey
scale 100x images. The densitometric value is inversely related to the intensity of the immunoreactivity. The number of lesions or NWM
regions analysed for each stage is indicated within parentheses in column one.The immunoreactivity within lesions was compared with the
corresponding NWM in multiple sclerosis and WMS cases (yP50.01 and P50.001).
CON WM=control white matter. EA=early active stage. LA= late active stage. MS=multiple sclerosis. NWM=normal white matter.
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Fig. 3 The oligodendrocytes, axons and hypertrophied astrocytes but not microglia lack COX-I immunoreactivity in Pattern III multiple
sclerosis lesions. a^ f: The left and right columns of images show COX-I and porin immunoreactivity, respectively. a and b: The double
immunofluorescent labelling of COX-I (a, green) and oligodendrocyte marker, CNPase (a, red) identifies oligodendrocytes lacking COX-I
immunoreactivity (a, arrowheads and insert) in the EA stage of Pattern III lesions. The cells with COX-I immunoreactivity in the EA stage
lack CNPase immunoreactivity (a, arrow). In serial sections, CNPase (red) immunoreactive oligodendrocytes (b, arrowhead and insert)
as well as numerous other cells in EA stage contain porin (green) immunoreactive elements. c and d: The double immunofluorescent
labelling of COX-I (c, green) and axonal markers [phosphorylated (SMI31) and non-phosphorylated (SMI32) neurofilaments in red] identifies
axons with only a small number of COX-I immunoreactive elements (c) in the LA stage of Pattern III lesions. In serial sections, the porin
elements (d, green) are more numerous than COX-I elements (c, green) within demyelinated axons in the LA stage of Pattern III lesions.
A confocal x^z image (d, insert) confirms the axonal location of the porin immunoreactive elements in the x^y images (d). e and f: The
mitochondrial proteins [COX-I (e) and porin (f)] are co-stained with a astrocyte marker, glial fibrillarry acidic protein, using chromogens
[DAB (brown) and Vector SG (grey), respectively]. The COX-I immunoreactive elements are absent in a proportion of hypertrophied
astrocytes (e) in Pattern III lesions. The hypertrophied astrocytes in serial sections contain abundant porin immunoreactivity (f). g^i: In
the LA stage of Pattern III lesions, the activated microglia distributed around the blood vessels and identified by the CD163 (h, red)
immunoreactivity contain COX-I immunoreactivity (g and i, green). a^ d: Confocal images. Scale bars = 10mm (a^f) and 50mm (g^i).
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(complex IV activity) and succinate dehydrogenase (com-
plex II activity). Since, frozen material from Pattern III
multiple sclerosis lesions were not available we investigated
hippocampal sections of a case with multiple mtDNA dele-
tions. Since the extent of mitochondrial defects in primary
mitochondrial disorders varies between cells in the nervous
system, we found low expression of mtDNA encoded
subunits (COX-I and complex I 20 kDa or ND6) in a subset
of pyramidal cells of the CA2 layer, while nuclear DNA
encoded proteins and the number of porin reactive
mitochondria were unaffected (Fig. 6a–e). Quantitative
studies on these cells, done by manual counting of
immunoreactive mitochondria, revealed a 60% decrease in
the number of COX-I reactive mitochondrial elements and
show the feasibility and reliability of the manual counting
method. This was confirmed by densitometry, showing a
significant decrease (P50.001) in COX-I reactivity within
affected cells in comparison to unaffected adjacent cells.
In a snap frozen section of the contralateral hippocampus
the enzyme histochemical analysis shows a proportion of
cells, lacking complex IV activity with normal complex II
activity (blue cells) and the remaining cells with complexes
IV and II activity (brown cells; Fig. 6f). Cells deficient in
COX-I and ND6 immunoreactivity or lacking complex IV
activity were absent in similarly processed control tissue.
These data indicate that the decrease in COX-I
Fig. 4 Pattern II multiple sclerosis lesions. a^ d: Sections containing a Pattern II multiple sclerosis lesion are stained for LFB (a), HLA (b),
MAG (c) and PLP (d). The EA stage of Pattern II lesions is identified by the perivenous demyelination, which are separated by partly
preserved myelin (a, arrows), and abundance of phagocytic macrophages (b) containing myelin debris (a, arrowheads). Both MAG (c)
and PLP (d) immunoreactivity are equally lost in the EA and LA stages (c and d, arrows and arrowheads, respectively) of Pattern II
lesions. e and f: At higher magnification the Pattern II tissue appears vacuolated with a general reduction in the number of porin
immunoreactive elements in EA (ee) and LA (eee) stages compared with NWM (e). f: The reduction in COX-I immunoreactive elements
in EA (ff) and LA (fff) stage of Pattern II lesions is relative to the reduction of porin (e) elements. Scale bars = 40mm (a), 8mm (b^d)
and 10mm (e and f).
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Fig. 5 WMS lesions.The three columns show immunoreactivity in NWM (left), EA (middle) and LA (right) stages of WMS tissue. a and b:
Both CNPase and MBP immunoreactivity are detectable in the NWM, whereas CNPase immunoreactivity is lost while MBP immuno-
reactivity is intact in the EA stage of WMS lesions. In the LA stage, both CNPase and MBP immunoreactivity are lost except within
phagocytic macrophages. c: The porin immunoreactive punctate elements are numerous in the NWM and EA stage. In the LA stage
of WMS lesions, there is severe tissue loss and mitochondria are mostly located in phagocytic macrophages. d^h: The number of
immunoreactive elements for all mitochondrial respiratory chain complex subunits (COX-I, complex I 20kDa or ND6, complex I 30kDa
and complex II 70kDa) except COX-IV appears decreased in EA stage compared with NWM. Furthermore, the majority of phagocytic
macrophages in LA stage show a decrease in immunoreactivity for the mitochondrial respiratory chain complex subunits (except for
COX-IV) despite the abundance of porin immunoreactive elements (ccc). Asterisk indicates subunits encoded by mtDNA. Scale
bars=10mm (a^h).
Table 4 Quantitation of immunoreactive elements of mitochondrial respiratory chain subunits in WMS lesions
Mean  SD
(No. of lesions)
Porin COX-I
(mtDNA)
COX-IV
(Nuclear)
Complex I
20kDa or
ND6 (mtDNA)
Complex I
30kDa
(Nuclear)
Complex II
70kDa
(Nuclear)
WMS 217.5817.67 186.64 7.23 155.6714.59 133.6210.17 162.1410.58 124.1315.09
NWM ^ 87 9.2 7311.6 6310.1 73 8.6 5913.9
(8^10) 133.8 4.6 145.93.7 159.03.6 159.9 4.5 153.3 4.3 162.4 4.6
WMS 182.4119.31 93.9617.52y 113.4411.27 51.3112.65y 102.2914.51 61.359.30
EA ^ 49 7.2y 63 9.3 27 7.7 5210.5y 3310.1
(7^9) 130.6 4.8 173.14.2 159.24.7 171.8 4.9y 168.43.9y 176.4 4.8y
The values indicated in the first line are the mean and standard deviation of the absolute number of punctate elements per 100x field
(6044mm2), second line are the mean and standard deviation of the percentages of porin elements containing respiratory chain complex
subunit immunoreactivity (in serial sections) and third line are the mean and standard deviation of the densitometric values of whole grey
scale 100x images. The densitometric value is inversely related to the intensity of the immunoreactivity. The number of lesions or NWM
regions analysed for each stage is indicated within parentheses in column one. The immunoreactivity within lesions was compared with
the corresponding NWM in multiple sclerosis and WMS cases (yP50.01 and P50.001).
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immunoreactivity like that seen in Pattern III multiple
sclerosis lesions is associated with a functional defect of the
respiratory chain.
Discussion
In this study, we explored mitochondrial defects in fixed
brain tissue from cases with multiple sclerosis by immu-
nohistochemistry detecting a number of mtDNA and
nuclear DNA encoded subunits of the respiratory chain
complexes. We then directly compared the changes in acute
multiple sclerosis lesions with those observed in WMS. In
comparison to the white matter of normal brains and the
NWM of multiple sclerosis tissue, we found two distinct
patterns in mitochondrial changes. The first was reflected
by a global reduction of mitochondrial density, seen also in
sections stained for porin. This was seen in all multiple
sclerosis and stroke tissues and apparently is due to the
increase in extracellular space due to oedema and tissue
loss/vacuolation. The second was a selective affection of
certain mitochondrial proteins in relation to the global
number of porin reactive mitochondria. This second pat-
tern of mitochondrial alterations appears to be relevant for
understanding mechanisms of tissue injury in the lesions.
In Pattern III lesions of multiple sclerosis patients, the
mitochondrial proteins which were most affected, were
COX-I and COX-IV. The analysis of the number of immu-
noreactive elements in serial sections shows that approx-
imately a quarter of mitochondrial elements in EA and half
of the mitochondrial elements in LA stages of Pattern III
lesions lack COX-I immunoreactivity. It is well established
that mtDNA encoded subunit-I of complex IV (COX-I) is
essential for the activity of complex IV or COX (Comi
et al., 1998; Bruno et al., 1999; Kollberg et al., 2005). There
was, however, also a deficiency of COX-IV (subunit IV of
complex IV) in approximately a quarter of mitochondrial
elements in Pattern III lesions. Although COX-IV is not a
catalytic component of complex IV, it is important for the
assembly of subunits as well as for the stability of complex
IV (Nijtmans et al., 1998; Taanman and Williams, 2001).
A defect in COX-I leads to degradation of unassembled
COX-IV, which may be the reason for a COX-IV defect in
LA stage of Pattern III lesions (Nijtmans et al., 1995).
Alternatively, COX-IV may succumb to the same process
that injures COX-I in Pattern III lesions. Hence, the
mitochondrial defects in Pattern III lesions most likely
impair activity, assembly and stability of complex IV. As
shown in the case with multiple deletions of mtDNA and
complex IV deficiency, the mitochondria devoid of COX-I
immunoreactivity in Pattern III lesions are likely to lack
complex IV activity.
The mitochondrial defects described above were seen in
oligodendrocytes, axons and astrocytes, but not in macro-
phages and microglia. Oligodendrocytes are more suscep-
tible to oxidative stress in vitro compared with astrocytes
and microglia despite similar inhibition of mitochondrial
activity (Mitrovic et al., 1994). This differential suscept-
ibility to oxidative stress may explain why oligodendrocytes
undergo apoptosis in Pattern III lesions, while astrocytes
are resistant. This difference may be due to astrocytes
Fig. 6 The loss of mtDNA encoded respiratory chain subunit immunoreactivity in fixed brain tissue and implications for complex IV
activity. (a^ e) immunoreactivity in serial sections of fixed hippocampus. (f) activity of complexes II and IV in the snap frozen contralateral
hippocampus.There are a number of cells containing complex II 70kDa, a nuclear encoded subunit, immunoreactivity (a) in the CA2 layer
of a fixed hippocampal section from a case with multiple deletions of mtDNA. In contrast, immunoreactivity for mtDNA encoded subunits
[complex I 20kDa or complex IV subunit I (COX-I)] is lacking in a proportion of cells, in serial sections (b and c, arrowheads and inserts).
The cells lacking complex I 20kDa or COX-I immunoreactivity (green) contain mitochondria (red) as shown by double immunofluorecent
labelling with porin (d and e, arrowheads). The functional implications of the lack of COX-I immunoreactivity in fixed brain tissue can be
clearly seen in a snap frozen section from the contralateral hippocampus where complex IV activity is lacking in a proportion of cells with
complex II activity (f, blue).
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being able to maintain ATP production through induction
of glycolysis (Almeida et al., 2001, 2004). Induction of
glycolysis in astrocytes with mitochondrial defects causes
an increase in lactate production (Almeida et al., 2001).
Indeed, magnetic resonance spectroscopic studies of Balo’s
type lesions have found consistently increased lactate peaks
(Lindquist et al., 2007; Mowry et al., 2007). Furthermore,
CSF lactate levels may be elevated in patients with primary
mitochondrial disorders (Jackson et al., 1995).
Mitochondrial injury may also be important in driving
axonal degeneration. In acutely demyelinated axons, the
efflux of sodium (Na+) entering through the redistributed
Na+ channels and ionic homeostasis are energy dependant
processes (Waxman, 2006). The demyelinated axons can be
protected from NO mediated degeneration, which involves
an energy deficient state, using Na+ channel blockers or
inhibitors of Na+/Ca2+ exchanger (Garthwaite et al., 2002;
Kapoor et al., 2003). Hence, the complex IV defect involv-
ing axons in Pattern III lesions may augment axonal
degeneration through an increase in intra-axonal Na+ and
imbalance of Ca2+.
What drives the complex IV defects in Pattern III lesions
needs further investigation. The differential expression of
mtDNA-encoded subunits is physiologically regulated at a
post-transcriptional level. The COX-I mRNA is rapidly
degraded in vitro compared to a number of other subunits
when exposed to NO (Wei et al., 2002). Hence, we
speculate that the mitochondrial defects in Pattern III
lesions identified in this study are due to post-transcrip-
tional modification of COX-I mRNA by NO and sub-
sequent degradation of unassembled COX-IV (Nijtmans
et al., 1995; Williams et al., 2001; Wei et al., 2002; Fukuda
et al., 2007). Alternative explanations include damage
to COX-I gene (mutations of COX-I gene) or selective
degradation of complex IV subunits. However, the above
hypothesis does not address why the mitochondrial defects
in acute lesions are confined to Pattern III in multiple
sclerosis. There is evidence that distinct inflammatory
pathways exist between Pattern II and Pattern III lesions.
The expression of chemokine receptors differs in Pattern II
from Pattern III lesions (Mahad et al., 2004). The microglia
appear to be activated via Toll-like receptors in the early
stages of Pattern III and not Pattern II lesions (Smiley et al.,
2001; Marik et al., 2007). These activated microglia, found
in close proximity to apoptotic oligodendrocytes, may
release a range of mediators (Barnett and Prineas, 2004;
Perry et al., 2007). Hence, the differences in immune
response and extent of NO production may explain the
selectivity of complex IV defects in acute multiple sclerosis
lesions.
Little is known about the state of mitochondrial
respiratory chain in WMS lesions. However, in vitro and
in vivo studies have identified a decrease in transcription of
mtDNA and nuclear DNA encoded subunits within 24 h of
exposure to hypoxia (Vijayasarathy et al., 2003; Piruat
and Lopez-Barneo, 2005; Fukuda et al., 2007). Accordingly,
we identify a decrease in a number of immunohistochemi-
cally detectable subunits of complexes I, II and IV except
COX-IV. What is intriguing about the profile of immuno-
histochemically detected mitochondrial respiratory chain
subunits in WMS lesions is the preservation of COX-IV
when COX-I is profoundly reduced (from 91% to 49%).
COX-IV has two isoforms (COX-IV-1, which is present
under physiological conditions and COX-IV-2). The
stabilisation of HIF-1 by hypoxia increases transcription
of COX-IV-2, which transfers electrons more efficiently
than COX-IV-1 (Fukuda et al., 2007). HIF-1 is
up-regulated in WMS lesions and early stages of Pattern
III lesions, where COX-IV is relatively preserved. HIF-1 is
minimal or absent in LA stage of Pattern III lesions, where
COX-IV is reduced (Marik et al., 2007). The monoclonal
antibody against COX-IV does not differentiate the iso-
forms. Hence, the stabilization of HIF-1 may explain the
difference in immunohistochemically detected COX-IV
between WMS and Pattern III lesions.
In conclusion, our study provides evidence for mito-
chondrial defects, which may at least in part explain the
hypoxia-like tissue injury seen in a subtype of multiple
sclerosis lesions. The data are consistent with the hypothesis
that radicals, produced by activated macrophages and
microglia, are a major driving force in the pathogenesis
of such lesions. The mechanism of tissue injury, described
here, may not be restricted to these fulminant lesions of
acute and early relapsing multiple sclerosis. Microarray
studies from cortical and white matter tissue of patients
with progressive multiple sclerosis showed up-regulation of
genes involved in (hypoxic) preconditioning (Graumann
et al., 2003) and decreased expression of mRNA for
mitochondrial proteins (Dutta et al., 2006). Furthermore,
the dominant loss of small calibre axons in multiple
sclerosis lesions suggests energy deficiency as a major
mechanism involved in axonal degeneration (DeLuca et al.,
2004; Stys, 2005). Thus, the mitochondrial alterations seen
in fulminant Pattern III multiple sclerosis lesions may in
milder form also drive oligodendrocyte and axonal injury
in the progressive stage of the disease.
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